Cogent Biosciences Inc COGT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:41 PM EDT
6.55quote price arrow down-0.06 (-0.83%)
Volume
746,573
52 week range
3.67 - 13.50
Loading...
  • Open6.58
  • Day High6.92
  • Day Low6.50
  • Prev Close6.61
  • 52 Week High13.50
  • 52 Week High Date06/14/23
  • 52 Week Low3.67
  • 52 Week Low Date12/11/23

Key Stats

  • Market Cap626.746M
  • Shares Out95.61M
  • 10 Day Average Volume1.26M
  • Dividend-
  • Dividend Yield-
  • Beta1.57
  • YTD % Change10.71

KEY STATS

  • Open6.58
  • Day High6.92
  • Day Low6.50
  • Prev Close6.61
  • 52 Week High13.50
  • 52 Week High Date06/14/23
  • 52 Week Low3.67
  • 52 Week Low Date12/11/23
  • Market Cap626.746M
  • Shares Out95.61M
  • 10 Day Average Volume1.26M
  • Dividend-
  • Dividend Yield-
  • Beta1.57
  • YTD % Change10.71

RATIOS/PROFITABILITY

  • EPS (TTM)-2.41
  • P/E (TTM)-2.72
  • Fwd P/E (NTM)-3.27
  • EBITDA (TTM)-205.86M
  • ROE (TTM)-99.26%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-28,717.31%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cogent Biosciences Inc

 

Profile

MORE
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to...
Peter Harwin
Independent Chairman of the Board
Andrew Robbins
President, Chief Executive Officer, Principal Executive Officer, Director
John Green
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Address
275 Wyman Street, 3Rd Floor
Waltham, MA
02451
United States

Top Peers

SYMBOLLASTCHG%CHG
NKTX
Nkarta Inc
7.27-0.52-6.68%
OLMA
Olema Pharmaceuticals Inc
9.74-0.16-1.62%
ALLO
Allogene Therapeutics Inc
3.42-0.04-1.01%
KRRO
Korro Bio Inc
65.19-1.59-2.38%
MLYS
Mineralys Therapeutics Inc
10.87+0.12+1.12%